Besides, TMB score was also significantly higher in patients with HNSCC harboring TP53 alteration receiving immunotherapy (median score, 7.45 vs 4.16, P < .001; Figure 1D). The gene discussed is TP53; the disease is head and neck squamous cell carcinoma.